Novel degrader of cancer-driving protein AKT slows prostate, breast tumors in mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      Several companies are working on compounds to inhibit AKT, a protein kinase that has been implicated in many cancers. Researchers at Mount Sinai are seeking to degrade the protein rather than just blocking it, and they have early evidence a drug they designed to do just that could hold promise in some prostate and breast cancers. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)